



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/973,451	10/09/2001	Myron K. Jacobson	NIAD-201.3 DIV - 7369 AP/NDH	
759	7590 06/04/2004		EXAMINER	
Fulbright & Jaworski LLP 666 Fifth Avenue			FETTEROLF, BRANDON J	
New York, NY 10103			ART UNIT	PAPER NUMBER
			1642	
			DATE MAILED: 06/04/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/973,451	JACOBSON ET AL.			
		Examiner	Art Unit			
		Brandon J Fetterolf, PhD	1642			
	The MAILING DATE of this communication app		1			
Period for Reply						
THE   - External after   - If the   - If NC   - Failu   Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.1. SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period for the to reply within the set or extended period for reply will, by statute the reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status			•			
1)[	Responsive to communication(s) filed on 19 M	larch 2004.				
·	· · · · · · · · · · · · · · · · · · ·	action is non-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
5) <u></u> 6)⊠	Claim(s) <u>67-80</u> is/are pending in the application 4a) Of the above claim(s) is/are withdray Claim(s) is/are allowed. Claim(s) <u>67-80</u> is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/o	wn from consideration.				
Applicati	on Papers					
9)[	The specification is objected to by the Examine	r.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority ι	ınder 35 U.S.C. § 119					
a)l	Acknowledgment is made of a claim for foreign All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau See the attached detailed Office action for a list	s have been received. s have been received in Application rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachmen	t(s)					
1) Notice 2) Notice 3) Inform	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

Art Unit: 1642

Jacobson et al.

Date of Priority: 5/01/1998

#### **DETAILED ACTION**

The response filed on March 9, 2004 to the restriction requirement of February 25, 2004 has been received. From this restriction requirement the applicant has elected Group VI, drawn to antibodies that bind to <u>HUMAN</u> protein, which encompasses Claims 67, 69, and 71, through SEQ ID NO: 3. The applicant further points out errors in the restriction requirement specifically why claims 70, 73, 74, 76, and 78 are not included in Group VI which all read on 67, through SEQ ID NO: 3. Although, the present examiner cannot address why the prior restriction requirement issued was not addressed and why the issues set forth in the 02/25/2004 restriction requirement were not set forth in the first restriction requirement. The present examiner has withdrawn the preceding restriction requirement filed on February 25, 2004 and the applicant's election filed on March 9, 2004.

Claims 1-66 were cancelled.

Thus, claims 67-80 are pending and are currently under examination.

### Claim Objections

Claim 72 is objected to of the following informalities: Claim 72 drawn to an isolated antibody of Claim 70, which binds specifically to a protein comprising amino acids 677-977 of SEQ ID NO:4 is repeated twice as Claim 72. Appropriate correction is required.

Claims 75-76 are objected to because of the following informalities: The claims refer to a non-elected claim 66. Appropriate correction is required.

# Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 09/973,451

Art Unit: 1642

Claim 71 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 71 is indefinite because it recites the phrase "stringent conditions". Stringent conditions are not defined by the claim (which reads on the full range of stringent conditions, that is from very permissive to very high stringency). Although the specification contemplates certain stringent conditions (page 16, line 18), it does not provide a limited definition for ascertaining the requisite degree of stringent conditions sought in the claims and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention and would not be able to determine the metes and bounds of the claims.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 67-80 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lin et. al. (J. Bio. Chem. 1997, Vol. 272, 11895-11901) in further view of Cambell, A.M. (Monoclonal Antibody Technology, Elsevier Science, NY, 1986, pages 1-33).

Lin et al. teach the isolation and characterization of the cDNA encoding Bovine Poly (ADP-ribose) Glycohydrolase (PARG) which catalyzes the release of ADP-ribose from an ADP ribose

polymer. Lin et al further teach the PARG amino acid sequence (page 11898) which appears to be encoded by a nucleotide sequence that is at least 80% identical to the nucleotide sequence set forth in SEQ ID NO:1. Lin et al further teach that the protein has a molecular weight greater than 100 kilodaltons (abstract).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to use the encoded PARG for the purposes of generating antibodies that specifically bind to the claimed peptides. One would have been motivated to do so because it is conventional in the art to generate antibodies following the cloning of a gene. Campbell, A..M. teaches (page 29) that it is "customary now for any group working on a macromolecule to both clone the genes coding for it and make monoclonal antibodies to it (sometimes without a clear objective for their application)". Further, it would have been conventional to one of ordinary skill in the art at the time the invention was made to isolate an Fc fragment or Fab fragment or Fab' fragment of an antibody. Lastly, the Board of Patent Appeals and interferences has taken the position that once an antigen has been isolated, the manufacture of monoclonal antibodies against it is *prima facie* obvious. See Ex parte Ehrlich, 3 USPQ 2d 1011 (PTO Bd. Pat. APP. & Int. 1987), Ex parte Sugimoto, 14 USPQ 2d 1312 (PTO Bd. Pat. APP. & Int. 1990).

#### No claims are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brandon J Fetterolf, PhD whose telephone number is (571)-272-2919. The examiner can normally be reached Monday through Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571)-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Brandon J Fetterolf, PhD Examiner Art Unit 1642

BF

GARY NICKOL
PRIMARY EXAMINER